Report Detail
Global Antibody Drug Conjugates (ADCs) Market Professional Survey Report 2019
- RnM3766375 |
- 20 September, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.
The global Antibody Drug Conjugates (ADCs) market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Antibody Drug Conjugates (ADCs) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antibody Drug Conjugates (ADCs) market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Antibody Drug Conjugates (ADCs) in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Antibody Drug Conjugates (ADCs) manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Segment by Application
Hospital
Clinics
Others
Table of Contents
Executive Summary
1 Industry Overview of Antibody Drug Conjugates (ADCs)
- 1.1 Definition of Antibody Drug Conjugates (ADCs)
- 1.2 Antibody Drug Conjugates (ADCs) Segment by Type
- 1.2.1 Global Antibody Drug Conjugates (ADCs) Production Growth Rate Comparison by Types (2014-2025)
- 1.2.2 Seattle Genetics Technology
- 1.2.3 ImmunoGen Technology
- 1.2.4 Immunomedics Technology
- 1.3 Antibody Drug Conjugates (ADCs) Segment by Applications
- 1.3.1 Global Antibody Drug Conjugates (ADCs) Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospital
- 1.3.3 Clinics
- 1.3.4 Others
- 1.4 Global Antibody Drug Conjugates (ADCs) Overall Market
- 1.4.1 Global Antibody Drug Conjugates (ADCs) Revenue (2014-2025)
- 1.4.2 Global Antibody Drug Conjugates (ADCs) Production (2014-2025)
- 1.4.3 North America Antibody Drug Conjugates (ADCs) Status and Prospect (2014-2025)
- 1.4.4 Europe Antibody Drug Conjugates (ADCs) Status and Prospect (2014-2025)
- 1.4.5 China Antibody Drug Conjugates (ADCs) Status and Prospect (2014-2025)
- 1.4.6 Japan Antibody Drug Conjugates (ADCs) Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia Antibody Drug Conjugates (ADCs) Status and Prospect (2014-2025)
- 1.4.8 India Antibody Drug Conjugates (ADCs) Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
- 2.1 Raw Material and Suppliers
- 2.2 Manufacturing Cost Structure Analysis of Antibody Drug Conjugates (ADCs)
- 2.3 Manufacturing Process Analysis of Antibody Drug Conjugates (ADCs)
- 2.4 Industry Chain Structure of Antibody Drug Conjugates (ADCs)
3 Development and Manufacturing Plants Analysis of Antibody Drug Conjugates (ADCs)
- 3.1 Capacity and Commercial Production Date
- 3.2 Global Antibody Drug Conjugates (ADCs) Manufacturing Plants Distribution
- 3.3 Major Manufacturers Technology Source and Market Position of Antibody Drug Conjugates (ADCs)
- 3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
- 4.1 Antibody Drug Conjugates (ADCs) Production and Capacity Analysis
- 4.2 Antibody Drug Conjugates (ADCs) Revenue Analysis
- 4.3 Antibody Drug Conjugates (ADCs) Price Analysis
- 4.4 Market Concentration Degree
5 Antibody Drug Conjugates (ADCs) Regional Market Analysis
- 5.1 Antibody Drug Conjugates (ADCs) Production by Regions
- 5.1.1 Global Antibody Drug Conjugates (ADCs) Production by Regions
- 5.1.2 Global Antibody Drug Conjugates (ADCs) Revenue by Regions
- 5.2 Antibody Drug Conjugates (ADCs) Consumption by Regions
- 5.3 North America Antibody Drug Conjugates (ADCs) Market Analysis
- 5.3.1 North America Antibody Drug Conjugates (ADCs) Production
- 5.3.2 North America Antibody Drug Conjugates (ADCs) Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America Antibody Drug Conjugates (ADCs) Import and Export
- 5.4 Europe Antibody Drug Conjugates (ADCs) Market Analysis
- 5.4.1 Europe Antibody Drug Conjugates (ADCs) Production
- 5.4.2 Europe Antibody Drug Conjugates (ADCs) Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe Antibody Drug Conjugates (ADCs) Import and Export
- 5.5 China Antibody Drug Conjugates (ADCs) Market Analysis
- 5.5.1 China Antibody Drug Conjugates (ADCs) Production
- 5.5.2 China Antibody Drug Conjugates (ADCs) Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China Antibody Drug Conjugates (ADCs) Import and Export
- 5.6 Japan Antibody Drug Conjugates (ADCs) Market Analysis
- 5.6.1 Japan Antibody Drug Conjugates (ADCs) Production
- 5.6.2 Japan Antibody Drug Conjugates (ADCs) Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan Antibody Drug Conjugates (ADCs) Import and Export
- 5.7 Southeast Asia Antibody Drug Conjugates (ADCs) Market Analysis
- 5.7.1 Southeast Asia Antibody Drug Conjugates (ADCs) Production
- 5.7.2 Southeast Asia Antibody Drug Conjugates (ADCs) Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia Antibody Drug Conjugates (ADCs) Import and Export
- 5.8 India Antibody Drug Conjugates (ADCs) Market Analysis
- 5.8.1 India Antibody Drug Conjugates (ADCs) Production
- 5.8.2 India Antibody Drug Conjugates (ADCs) Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India Antibody Drug Conjugates (ADCs) Import and Export
6 Antibody Drug Conjugates (ADCs) Segment Market Analysis (by Type)
- 6.1 Global Antibody Drug Conjugates (ADCs) Production by Type
- 6.2 Global Antibody Drug Conjugates (ADCs) Revenue by Type
- 6.3 Antibody Drug Conjugates (ADCs) Price by Type
7 Antibody Drug Conjugates (ADCs) Segment Market Analysis (by Application)
- 7.1 Global Antibody Drug Conjugates (ADCs) Consumption by Application
- 7.2 Global Antibody Drug Conjugates (ADCs) Consumption Market Share by Application (2014-2019)
8 Antibody Drug Conjugates (ADCs) Major Manufacturers Analysis
- 8.1 Roche
- 8.1.1 Roche Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.1.2 Roche Product Introduction, Application and Specification
- 8.1.3 Roche Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.1.4 Main Business and Markets Served
- 8.2 Pfizer
- 8.2.1 Pfizer Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.2.2 Pfizer Product Introduction, Application and Specification
- 8.2.3 Pfizer Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.2.4 Main Business and Markets Served
- 8.3 Novartis
- 8.3.1 Novartis Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.3.2 Novartis Product Introduction, Application and Specification
- 8.3.3 Novartis Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.3.4 Main Business and Markets Served
- 8.4 Genmab
- 8.4.1 Genmab Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.4.2 Genmab Product Introduction, Application and Specification
- 8.4.3 Genmab Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.4.4 Main Business and Markets Served
- 8.5 Bayer
- 8.5.1 Bayer Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.5.2 Bayer Product Introduction, Application and Specification
- 8.5.3 Bayer Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.5.4 Main Business and Markets Served
- 8.6 Seattle Genetics
- 8.6.1 Seattle Genetics Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.6.2 Seattle Genetics Product Introduction, Application and Specification
- 8.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.6.4 Main Business and Markets Served
- 8.7 Takeda Pharmaceuticals
- 8.7.1 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.7.2 Takeda Pharmaceuticals Product Introduction, Application and Specification
- 8.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.7.4 Main Business and Markets Served
- 8.8 AbbVie
- 8.8.1 AbbVie Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.8.2 AbbVie Product Introduction, Application and Specification
- 8.8.3 AbbVie Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.8.4 Main Business and Markets Served
- 8.9 AbGenomics
- 8.9.1 AbGenomics Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.9.2 AbGenomics Product Introduction, Application and Specification
- 8.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.9.4 Main Business and Markets Served
- 8.10 ADC Therapeutics
- 8.10.1 ADC Therapeutics Antibody Drug Conjugates (ADCs) Production Sites and Area Served
- 8.10.2 ADC Therapeutics Product Introduction, Application and Specification
- 8.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.10.4 Main Business and Markets Served
- 8.11 Astellas Pharma
- 8.12 Kairos Therapeutics
9 Development Trend of Analysis of Antibody Drug Conjugates (ADCs) Market
- 9.1 Global Antibody Drug Conjugates (ADCs) Market Trend Analysis
- 9.1.1 Global Antibody Drug Conjugates (ADCs) Market Size (Volume and Value) Forecast 2019-2025
- 9.2 Antibody Drug Conjugates (ADCs) Regional Market Trend
- 9.2.1 North America Antibody Drug Conjugates (ADCs) Forecast 2019-2025
- 9.2.2 Europe Antibody Drug Conjugates (ADCs) Forecast 2019-2025
- 9.2.3 China Antibody Drug Conjugates (ADCs) Forecast 2019-2025
- 9.2.4 Japan Antibody Drug Conjugates (ADCs) Forecast 2019-2025
- 9.2.5 Southeast Asia Antibody Drug Conjugates (ADCs) Forecast 2019-2025
- 9.2.6 India Antibody Drug Conjugates (ADCs) Forecast 2019-2025
- 9.3 Antibody Drug Conjugates (ADCs) Market Trend (Product Type)
- 9.4 Antibody Drug Conjugates (ADCs) Market Trend (Application)
- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.3 Antibody Drug Conjugates (ADCs) Customers
11 Market Dynamics
- 11.1 Market Trends
- 11.2 Opportunities
- 11.3 Market Drivers
- 11.4 Challenges
- 11.5 Influence Factors
12 Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Antibody Drug Conjugates (ADCs). Industry analysis & Market Report on Antibody Drug Conjugates (ADCs) is a syndicated market report, published as Global Antibody Drug Conjugates (ADCs) Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Antibody Drug Conjugates (ADCs) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
